Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Maintenance Ofatumumab Approved in CLL

January 19th 2016

FDA Approves Maintenance Ofatumumab in CLL

January 19th 2016

The FDA has approved ofatumumab (Arzerra) for the extended treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial response following at least two lines of therapy.

Emerging Chronic Lymphocytic Leukemia Therapies

January 19th 2016

Venetoclax in Chronic Lymphocytic Leukemia

January 19th 2016

Evaluating the Role of Idelalisib in CLL

January 19th 2016

Mechanisms of Ibrutinib Resistance in CLL

January 19th 2016

Pharmacovigilance with Ibrutinib in CLL

January 19th 2016

Using Ibrutinib in Chronic Lymphocytic Leukemia

January 19th 2016

Small-Molecule Inhibitors: Ibrutinib in CLL

January 19th 2016

The Role of Ofatumumab in the Treatment of CLL

January 19th 2016

CD-20 Antibodies in Chronic Lymphocytic Leukemia

January 19th 2016

Chemoimmunotherapy in Chronic Lymphocytic Leukemia

January 19th 2016

The Value of CT Scans in Chronic Lymphocytic Leukemia

January 19th 2016

Clinical Objectives in Chronic Lymphocytic Leukemia Treatment

January 19th 2016

Front-Line Chemoimmunotherapy in CLL

January 19th 2016

Detecting Chromosomal Abnormalities in CLL

January 19th 2016

Prognostic Factors and the Impact of New Therapies

January 19th 2016

Ublituximab Is Combined With Ibrutinib in High-Risk CLL Study

January 13th 2016

Researchers are combining the novel CD20-targeting agent ublituximab (TG-1101) with ibrutinib to determine whether the regimen can improve outcomes in CLL, particularly for patients whose disease has high-risk features.

FDA Grants Venetoclax Priority Review in Second-Line CLL

January 12th 2016

The FDA has assigned a priority review to venetoclax for use in adults with chronic lymphocytic leukemia, including patients with a 17p deletion, following at least 1 prior therapy.

Byrd on Promise of Acalabrutinib in CLL

December 21st 2015

John C. Byrd, MD, discusses the second-generation BTK inhibitor acalabrutinib, which had a 95% response rate in patients with relapsed/refractory chronic lymphocytic leukemia.